Tebipenem, the first oral carbapenem antibiotic

Expert Review of Anti-infective Therapy
Akash JainMichael J Pucci

Abstract

Infections caused by antibiotic-resistant pathogens, particularly Gram-negative bacteria, have become increasingly challenging to successfully treat. The beta-lactam antibiotic subclass, the carbapenems, have proven valuable for the treatment of such Gram-negative bacterial infections due to their spectrum and β-lactamase stability properties. However, all marketed carbapenems to date are parenterally administered to adult patients. Areas covered: One carbapenem, tebipenem-pivoxil (TBPM-PI), is an oral prodrug that was approved in Japan for pediatric use only in 2009. This review summarizes preclinical and clinical data for TBPM-PI, which is now in clinical development again this time for use as the first oral carbapenem available for treatment of bacterial infections in adult patients. Expert commentary: There is an urgent unmet need with an increasing prevalence of fluoroquinolone-resistant and ESBL-producing Gram-negative pathogens in the hospital and community setting. Carbapenems have traditionally been considered the drugs of choice for infections caused by enterobacteria producing ESBL and AmpC enzymes because they are not affected by these resistance mechanisms. The carbapenem, TBPM-PI, offers an oral option, particular...Continue Reading

References

Jul 14, 2001·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·T Mazzei, P Dentico
Jun 22, 2005·The Journal of Antimicrobial Chemotherapy·Dominique L MonnetNiels Frimodt-Møller
Jul 13, 2006·The Journal of Antibiotics·Takeshi IsodaYoshimitsu Nagao
Apr 4, 2007·Expert Review of Anti-infective Therapy·Kristen N SchurekGeorge G Zhanel
May 10, 2007·Drugs·George G ZhanelJames A Karlowsky
Feb 10, 2009·Current Medicinal Chemistry·Matteo BassettiClaudio Viscoli
Aug 3, 2010·Journal of Infection and Chemotherapy : Official Journal of the Japan Society of Chemotherapy·Momoko FujisakiKeizo Yamaguchi
Feb 1, 2011·International Journal of Antimicrobial Agents·David M LivermoreMarina Warner
Aug 24, 2011·Antimicrobial Agents and Chemotherapy·Krisztina M Papp-WallaceRobert A Bonomo
Oct 18, 2011·Emerging Infectious Diseases·Patrice NordmannLaurent Poirel
Jan 26, 2013·Annals of the New York Academy of Sciences·Karen Bush
Apr 9, 2013·Journal of Infection and Chemotherapy : Official Journal of the Japan Society of Chemotherapy·Takeshi TajimaKeisuke Sunakawa
Aug 28, 2013·International Journal of Antimicrobial Agents·Chakkraphong SeenamaVisanu Thamlikitkul
Jan 1, 2014·Antimicrobial Agents and Chemotherapy·Sarah M DrawzRobert A Bonomo
Jul 2, 2014·Journal of Chromatographic Science·Judyta Cielecka-PiontekMagdalena Paczkowska
Nov 18, 2014·Chromatographia·Przemysław ZalewskiJudyta Cielecka-Piontek
Aug 12, 2015·Antimicrobial Agents and Chemotherapy·Amit KaushikGyanu Lamichhane
Jan 12, 2016·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·Qi YaoHongbo Yang
Feb 13, 2016·The Journal of Antimicrobial Chemotherapy·Marlen AdlerLinus Sandegren
May 22, 2016·Infectious Disease Clinics of North America·Krisztina M Papp-Wallace, Robert A Bonomo
Jun 23, 2016·Cold Spring Harbor Perspectives in Medicine·Karen Bush, Patricia A Bradford
Oct 16, 2016·Cold Spring Harbor Perspectives in Medicine·Robert A Bonomo
Nov 20, 2016·Oral Diseases·P Holmstrup, B Klausen
Feb 28, 2017·Journal of Infection and Chemotherapy : Official Journal of the Japan Society of Chemotherapy·Hiroshi SakataUNKNOWN World's First Oral Carbapenem Study Group
Mar 18, 2017·Drugs·Darren Wong, David van Duin
Mar 23, 2017·European Journal of Medicinal Chemistry·Mohammed I El-GamalAmany Bahaaeldin
May 2, 2017·Clinics in Laboratory Medicine·Alina Iovleva, Yohei Doi
May 31, 2017·Future Microbiology·Rohini MattooGyanu Lamichhane
Feb 16, 2018·Clinical Microbiology Reviews·Jesús Rodríguez-BañoAlvaro Pascual

❮ Previous
Next ❯

Citations

Feb 6, 2019·Antimicrobial Agents and Chemotherapy·Evelyne LacasseFrançois Malouin
Dec 14, 2019·Current Opinion in Infectious Diseases·David L PatersonPatrick N A Harris
Jun 7, 2020·Biomolecules·Antonella R PalaciosAlejandro J Vila
May 20, 2020·Antimicrobial Agents and Chemotherapy·Nicole CotroneoMichael J Pucci
Aug 25, 2020·Current Emergency and Hospital Medicine Reports·Boris Garber, Jonathan Glauser
Aug 9, 2020·Future Microbiology·Mehmet Akif GunAhmet Yilmaz Coban
Oct 2, 2020·European Journal of Medicinal Chemistry·Lidia Moreira LimaEliezer J Barreiro
Feb 18, 2021·Antimicrobial Agents and Chemotherapy·Nicholas P ClaytonMichael J Pucci
Jul 12, 2021·The Lancet Infectious Diseases·Maria F MojicaRobert A Bonomo
Aug 7, 2021·Infectious Diseases and Therapy·Balaji VeeraraghavanRani Diana Sahni
Sep 18, 2021·The Journal of Antimicrobial Chemotherapy·Elli MylonaStephen Baker

❮ Previous
Next ❯

Related Concepts

Related Feeds

Beta-lactamase Inhibitors

Beta-lactamase inhibitors are a class of antibiotics that inhibit beta-lactamases, a family of enzymes involved in bacterial resistance to beta-lactam antibiotics. Here is the latest research.

Beta-lactamase Inhibitors (ASM)

Beta-lactamase inhibitors are a class of antibiotics that inhibit beta-lactamases, a family of enzymes involved in bacterial resistance to beta-lactam antibiotics. Here is the latest research.

Carbapenems (ASM)

Carbapenems are members of the beta lactam class of antibiotics and are used for the treatment of severe or high-risk bacterial infections. Discover the latest research on carbapenems here.

Carbapenems

Carbapenems are members of the beta lactam class of antibiotics and are used for the treatment of severe or high-risk bacterial infections. Discover the latest research on carbapenems here.

Antimicrobial Resistance (ASM)

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Antimicrobial Resistance

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.